Propoxyphene and the risk of out‐of‐hospital death. (14th February 2013)
- Record Type:
- Journal Article
- Title:
- Propoxyphene and the risk of out‐of‐hospital death. (14th February 2013)
- Main Title:
- Propoxyphene and the risk of out‐of‐hospital death
- Authors:
- Ray, Wayne A.
Murray, Katherine T.
Kawai, Vivian
Graham, David J.
Cooper, William O.
Hall, Kathi
Michael Stein, Charles - Abstract:
- <abstract abstract-type="main"> <title>ABSTRACT</title> <sec id="pds3411-sec-0001" sec-type="section"> <title>Purpose</title> <p>The opioid analgesic propoxyphene was withdrawn from the US market in 2010, motivated by concerns regarding fatality in overdose and adverse cardiac effects, including prolongation of the QT interval. These concerns were based on case reports, summary vital statistics, and surrogate endpoint studies.</p> </sec> <sec id="pds3411-sec-0002" sec-type="section"> <title>Methods</title> <p>Using the linked Tennessee Medicaid database (1992–2007), we conducted a retrospective cohort study that compared risk of sudden cardiac, medication toxicity, and total out‐of‐hospital death for propoxyphene users with that for comparable nonusers of any prescribed opioid analgesic and users of hydrocodone, an opioid with similar indications. Cohort members had 1 873 500 propoxyphene prescriptions, 1 873 500 matched nonuser control periods, and 936 750 matched hydrocodone prescriptions.</p> </sec> <sec id="pds3411-sec-0003" sec-type="section"> <title>Results</title> <p>Current propoxyphene users had no increased risk for sudden cardiac death (versus nonusers: hazard ratio [HR] = 1.00 [0.81–1.23]; versus current hydrocodone users: HR = 0.91 [0.68–1.21]) but did have increased risk for medication toxicity deaths (versus nonusers: HR = 1.85 [1.07–3.19], <italic>p</italic> = 0.027; versus current hydrocodone users: HR = 2.10 [0.87–5.10], <italic>p</italic> = 0.100). Because<abstract abstract-type="main"> <title>ABSTRACT</title> <sec id="pds3411-sec-0001" sec-type="section"> <title>Purpose</title> <p>The opioid analgesic propoxyphene was withdrawn from the US market in 2010, motivated by concerns regarding fatality in overdose and adverse cardiac effects, including prolongation of the QT interval. These concerns were based on case reports, summary vital statistics, and surrogate endpoint studies.</p> </sec> <sec id="pds3411-sec-0002" sec-type="section"> <title>Methods</title> <p>Using the linked Tennessee Medicaid database (1992–2007), we conducted a retrospective cohort study that compared risk of sudden cardiac, medication toxicity, and total out‐of‐hospital death for propoxyphene users with that for comparable nonusers of any prescribed opioid analgesic and users of hydrocodone, an opioid with similar indications. Cohort members had 1 873 500 propoxyphene prescriptions, 1 873 500 matched nonuser control periods, and 936 750 matched hydrocodone prescriptions.</p> </sec> <sec id="pds3411-sec-0003" sec-type="section"> <title>Results</title> <p>Current propoxyphene users had no increased risk for sudden cardiac death (versus nonusers: hazard ratio [HR] = 1.00 [0.81–1.23]; versus current hydrocodone users: HR = 0.91 [0.68–1.21]) but did have increased risk for medication toxicity deaths (versus nonusers: HR = 1.85 [1.07–3.19], <italic>p</italic> = 0.027; versus current hydrocodone users: HR = 2.10 [0.87–5.10], <italic>p</italic> = 0.100). Because toxicity deaths were a small proportion of study deaths, total out‐of‐hospital mortality differed by less than 10% between the study groups and was not significantly elevated for propoxyphene (versus nonusers: HR = 1.09 [0.95–1.25]; versus current hydrocodone users: HR = 1.06 [0.87–1.29] ).</p> </sec> <sec id="pds3411-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our findings support the concern that propoxyphene has greater toxicity in overdose but do not provide evidence that it increases the risk of sudden cardiac death. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p> </sec> </abstract> … (more)
- Is Part Of:
- Pharmacoepidemiology and drug safety. Volume 22:Number 4(2013:Apr.)
- Journal:
- Pharmacoepidemiology and drug safety
- Issue:
- Volume 22:Number 4(2013:Apr.)
- Issue Display:
- Volume 22, Issue 4 (2013)
- Year:
- 2013
- Volume:
- 22
- Issue:
- 4
- Issue Sort Value:
- 2013-0022-0004-0000
- Page Start:
- 403
- Page End:
- 412
- Publication Date:
- 2013-02-14
- Subjects:
- Pharmacoepidemiology -- Periodicals
Chemotherapy -- Periodicals
Epidemiology -- Periodicals
615.705 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/pds.3411 ↗
- Languages:
- English
- ISSNs:
- 1053-8569
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.248000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3848.xml